ES2587745T3 - Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer - Google Patents
Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer Download PDFInfo
- Publication number
- ES2587745T3 ES2587745T3 ES13745668.7T ES13745668T ES2587745T3 ES 2587745 T3 ES2587745 T3 ES 2587745T3 ES 13745668 T ES13745668 T ES 13745668T ES 2587745 T3 ES2587745 T3 ES 2587745T3
- Authority
- ES
- Spain
- Prior art keywords
- halogen
- substituted
- alkyl
- hydrogen
- 7alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un compuesto de fórmula**Fórmula** en el que Ar es fenilo, piridinilo, 2,3-dihidro-benzo[1,4]dioxinilo, 1,3-dihidro-indol-2-ona, pirazinilo, isoxazol-3-ilo, imidazolilo, tiofenilo o pirimidinilo; R es alquilo-C1-7 o alquilo-C1-7 sustituido por halógeno; R1 es hidrógeno, halógeno, hidroxi, alcoxi-C1-7, alquilo-C1-7 y alcoxi-C1-7 sustituido por halógeno; R2 es hidrógeno, alquilo-C1-7; R3 es hidrógeno, halógeno, alquilo-C1-7, alquilo-C1-7 sustituido por halógeno, alcoxi-C1-7, alcoxi-C1-7 sustituido por halógeno, O(CH2)mO(CH2)mO-alquilo-C1-7 sustituido por halógeno, ciano, alcoxi-C1-7 sustituido por hidroxi, alqueniloxi-C1-7, C(O)OH, heterocicloalquilo seleccionado de morfolinilo, pirrolidinilo o pirrolidin-2-ona, o es heteroarilo seleccionado entre imidazolilo sustituido por alquilo-C1-7, o es NR'R" y R'/R" son independientemente uno del otro hidrógeno o alquilo-C1-7 o-C(O)-alquilo-C1-7; o es-C(O)NR4R5 y R4 es hidrógeno o alquilo-C1-7 y R5 es hidrógeno, alquilo-C1-7, alquenilo-C1-7,-(CH2)mO-alquilo-C1-7 sustituido por halógeno, alquilo-C1-7 sustituido por halógeno,-(CH2)n-fenilo opcionalmente sustituido por halógeno,-(CH2) mNHC(O)-alquilo-C1-7, o-(CH2)mNH2, o R4 y R5 pueden formar junto con el átomo de N al que están unidos, un anillo de piperidina o azetidina, que puede estar sustituido por halógeno; o es-C(O)O-alquilo-C1-7 sustituido por halógeno; n es 1 o 2; m es 1, 2 o 3; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o su correspondiente enantiómero y/o isómeros ópticos de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12180367 | 2012-08-14 | ||
| EP12180367 | 2012-08-14 | ||
| PCT/EP2013/066447 WO2014026881A1 (en) | 2012-08-14 | 2013-08-06 | Imidazo[2,1]thiazol-3-one derivatives useful as diagnostic agents for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2587745T3 true ES2587745T3 (es) | 2016-10-26 |
Family
ID=46851292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13745668.7T Active ES2587745T3 (es) | 2012-08-14 | 2013-08-06 | Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150157739A1 (es) |
| EP (1) | EP2885306B1 (es) |
| JP (1) | JP6228980B2 (es) |
| KR (1) | KR20150042787A (es) |
| CN (1) | CN104411709B (es) |
| BR (1) | BR112015000447A2 (es) |
| CA (1) | CA2876459A1 (es) |
| ES (1) | ES2587745T3 (es) |
| HK (1) | HK1206343A1 (es) |
| MX (1) | MX2015001546A (es) |
| RU (1) | RU2015106437A (es) |
| WO (1) | WO2014026881A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105560831A (zh) * | 2016-01-08 | 2016-05-11 | 肖鉴 | 一种治疗不孕不育的中药组合物 |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| CN109475648B (zh) | 2016-07-22 | 2023-03-14 | Ac免疫有限公司 | 用于成像tau蛋白聚集体的化合物 |
| CN110506045B (zh) * | 2017-04-12 | 2023-01-13 | 帝斯曼知识产权资产管理有限公司 | 制备咪唑并噻唑酮化合物的方法 |
| WO2019145292A1 (en) | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100119599A1 (en) * | 2006-12-08 | 2010-05-13 | Archer Pharmaceuticals, Inc. | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
| EP2338059B1 (en) * | 2008-09-23 | 2015-04-08 | WisTa Laboratories Ltd. | Ligands for aggregated tau molecules |
| WO2010111303A2 (en) * | 2009-03-23 | 2010-09-30 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological disorders |
| WO2012078909A1 (en) * | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Thiazolpyrimidine proteostasis regulators |
-
2013
- 2013-08-06 MX MX2015001546A patent/MX2015001546A/es unknown
- 2013-08-06 JP JP2015526931A patent/JP6228980B2/ja not_active Expired - Fee Related
- 2013-08-06 ES ES13745668.7T patent/ES2587745T3/es active Active
- 2013-08-06 CN CN201380035088.4A patent/CN104411709B/zh not_active Expired - Fee Related
- 2013-08-06 RU RU2015106437A patent/RU2015106437A/ru not_active Application Discontinuation
- 2013-08-06 WO PCT/EP2013/066447 patent/WO2014026881A1/en active Application Filing
- 2013-08-06 EP EP13745668.7A patent/EP2885306B1/en not_active Not-in-force
- 2013-08-06 KR KR20157003508A patent/KR20150042787A/ko not_active Application Discontinuation
- 2013-08-06 BR BR112015000447A patent/BR112015000447A2/pt active Search and Examination
- 2013-08-06 CA CA2876459A patent/CA2876459A1/en not_active Abandoned
-
2015
- 2015-02-13 US US14/621,903 patent/US20150157739A1/en not_active Abandoned
- 2015-07-21 HK HK15106928.7A patent/HK1206343A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014026881A1 (en) | 2014-02-20 |
| RU2015106437A (ru) | 2016-10-10 |
| JP6228980B2 (ja) | 2017-11-08 |
| EP2885306A1 (en) | 2015-06-24 |
| MX2015001546A (es) | 2015-05-11 |
| CN104411709B (zh) | 2016-08-24 |
| JP2015524830A (ja) | 2015-08-27 |
| EP2885306B1 (en) | 2016-06-01 |
| US20150157739A1 (en) | 2015-06-11 |
| CN104411709A (zh) | 2015-03-11 |
| CA2876459A1 (en) | 2014-02-20 |
| HK1206343A1 (zh) | 2016-01-08 |
| KR20150042787A (ko) | 2015-04-21 |
| BR112015000447A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2587745T3 (es) | Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR092684A1 (es) | Compuestos de sulfonamida sustituidos | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 |